Insys Therapeutics Stock Price Up 5.4% Following Insider Buying Activity (INSY)
Insys Therapeutics (NASDAQ:INSY) rose 5.4% during mid-day trading on Monday after an insider bought additional shares in the company, AnalystRatings.Net reports. The company traded as high as $37.73 and last traded at $36.62, with a volume of 443,803 shares. The stock had previously closed at $34.75.
Specifically, Director Theodore H. Stanley purchased 3,000 shares of the stock in a transaction dated Wednesday, August 13th. The stock was purchased at an average price of $33.93 per share, with a total value of $101,790.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
The stock’s 50-day moving average is $28.49 and its 200-day moving average is $34.69. The company has a market cap of $1.254 billion and a P/E ratio of 24.13.
Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings results on Tuesday, August 12th. The company reported $0.58 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.30 by $0.28. The company had revenue of $55.70 million for the quarter, compared to the consensus estimate of $52.77 million. On average, analysts predict that Insys Therapeutics will post $1.08 earnings per share for the current fiscal year.
Insys Therapeutics, Inc, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.